Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis

Miscarriage Clinical Trial

— RH-PL  

Official title:

Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05936333
• Other study ID #: APHP221169
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 2023
• Est. completion date: January 2025

Study information

• Verified date: June 2023
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Alexandra LETOURNEAU, Doctor
• Phone: 331 45 37 44 76
• Email: letourneau.alexandra[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic histiocytic intervillositis (CHI) is a rare condition with an incidence of 5 in 10,000 pregnancies. This rare condition is associated with placental inflammatory lesions leading to severe and recurrent obstetrical complications: intrauterine growth retardation (IUGR), fetal death in utero and miscarriage. The pathophysiological mechanisms of CHI are poorly understood, while the empirical treatments prescribed to prevent recurrence are cumbersome and of poor efficacy. Recent findings suggest that an alloimmune response may play a role. In a recent work, the investigators have demonstrated the role of maternal alloantibodies directed against fetal HLA antigens in two patients followed for recurrent IUGR associated with CHI. Their work suggests that a humoral alloimmune response directed against fetal HLA antigens mimics an allograft rejection process. The investigators propose to extend the preliminary results obtained in these patients to provide new insights into the pathophysiological mechanisms of CHI, and eventually to predict the risks of fetal loss.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Family Inclusion Criteria:

• Mother and father = 18 years old
• For mothers in the CHI group :
• History of a normal pregnancy (full term, alive child) or IUGR/MFIU or miscarriage(s) or abortion followed by at least 1 obstetrical complication such as IUGR, MFIU, miscarriage
• Diagnosis of chronic histiocytic intervillitis made by placental anatomopathological examination with CD68+ marking
• For the mothers of the antiphospholipid syndrom group
• History of miscarriage(s)
• Having an anti-phospholipid syndrome
• For mothers in the normal pregnancy group:
• Third consecutive pregnancy of normal course, at term (= 36 weeks of amenorrhea) with eutrophic child For the mother and father: o Consent to participate in the study and for the participation in the study of at least one child and/or the use of existing samples (placenta / fetal DNA) from at least one previous pregnancy with CHI for the CHI group or at least one previous miscarriage for the APS group For the father: o Father of the last pregnancy and of the child(ren) participating in the study

Exlusion criteria :

• For mothers in the normal pregnancy group:

o Suspected or confirmed intra-amniotic infection

• For all the mothers:
• History of blood transfusion
• History of allogeneic organ transplantation
• For the mother and the father:
• Person under legal protection (guardianship, curatorship)

Related Conditions & MeSH terms

• Abortion, Spontaneous
• Fetal Death
• Fetal Growth Retardation
• Intrauterine Growth Retardation
• Miscarriage

Intervention

Procedure:
• Biological collection
up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth

Locations

Country	Name	City	State
France	Antoine Béclère Hospital	Clamart

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients diagnosed with CHI, defined by the concomitant presence of the 3 criteria required to evoke humoral alloimmune rejection for this pathology	Proportion of patients diagnosed with CHI, defined by the concomitant presence of the 3 criteria required to evoke humoral alloimmune rejection for this pathology, namely CD68+ infiltrate, AND C4d deposits on the trophoblastic villi AND the presence of at least one FSA (fetus-specific antibody, directed against fetal HLA antigens in the maternal blood) with an elevated level, defined by a Mean Fluorescence Intensity (MFI) > 10,000).; This proportion of patients observed in CHI carriers will be compared to the proportion of patients with the concomitant presence of the same 3 criteria observed in the other two control groups.	up to 6 months
Secondary	To measure the FSA levels by Mean Fluorescence Intensity for the different obstetrical complications: intrauterine growth retardation (IUGR), fetal death in utero and abortion for IUGR.		up to 6 months
Secondary	to measure the correlation between fetus-specific antibody level by Mean Fluorescence Intensity and the severity and/or precocity of obstetrical complications		up to 6 months
Secondary	measure of semi-quantitative graduation of C4d in placenta compared to percentage of villositis		up to 6 months
Secondary	measure of semi-quantitative graduation of CD68+ infiltrate in placenta compared to surface and number of involved villositis		up to 6 months
Secondary	To measure the expression of HLA class I and II molecules by placental villi by ß2-microglobulin and HLA-DR labelling		up to 6 months
Secondary	Epitope analysis with algorithm developped by laboratoire HLA de St Louis (Pr JL Taupin)	Epitope analysis with algorithm developped by laboratoire HLA de St Louis (Pr JL Taupin) to determine whether an antibody response against a limited number of epitopes present during a first pregnancy that resulted in a healthy child can explain immunization against both paternal alleles	up to 6 months